AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00668096 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT00857818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks
Study NCT00857818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oanzapine, risperidone, or quetiapine
Description: Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks
Study NCT00949195 — intervention group
Intervention type: OTHER
Intervention: Measure pulmonary artery pressure change during exercise
Description: Semi-supine echocardiography test
Study NCT00949195 — intervention group
Intervention type: OTHER
Intervention: Pulmonary pressure response during exercise
Description: Semi-supine echocardiography test
Study NCT05208424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Coronary angiography
Description: Invasive coronary angiography
Study NCT01834924 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: HELPix
Description: Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
Study NCT03572270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: AMH test
Description: Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
Study NCT03572270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: AMH test
Description: Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
Study NCT03572270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: pelvic ultrasound
Description: Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
Study NCT03730350 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Hypnosis
Description: Hypnosis guidance and audio tracks aimed at promoting pain relief, reducing distress and anxiety, and facilitating sleep will be provided for independent use, with daily practice recommended. Each hypnosis session will be 20-25 minutes long. The scripts for these sessions have been developed based on the clinical literature (e.g., Elkins, 2014) and are already in use with patients of the pain service.
Study NCT01264783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60
Description: RNS60 for intravenous administration
Study NCT02081703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AYX1 Injection 660 mg / 6 mL
Description: 6 mL solution for intrathecal injection with 660 mg of AYX1
Study NCT03572270 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: pelvic ultrasound
Description: Blood test and pelvic ultrasound are performed at each visit to evaluate ovarian reserve
Study NCT01615224 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: misoprostol
Description: repeated doses of misoprostol. 400mcg of oral misoprostol given at 3, 5, 7 and 9 hours.
Study NCT01596842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acid ethylester 90
Description: Omega-3 fatty acid ethylester 90, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
Study NCT01596842 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil
Description: Olive oil, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
Study NCT01596842 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: cholecalciferol
Description: if baseline 25-hydroxyvitamin D levels are \< 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks
Study NCT01596842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: if baseline 25-hydroxyvitamin D levels are \< 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks
Study NCT01387295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin, capecitabine, trastuzumab
Description: Oxaliplatin intrahepatic capecitabine and trastuzumab systemic
Study NCT03392155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training & Nutrition
Description: Exercise at moderate to high intensities and diet education/counseling
Study NCT00816907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500 mg to 1,000 mg taken twice daily for 16 weeks
Study NCT00816907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 to 2 placebo capsules taken twice daily for 16 weeks
Study NCT01264783 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% normal saline for injection
Study NCT02081703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AYX1 Injection 1100 mg / 10 mL
Description: 10 mL solution for intrathecal injection with 1100 mg of AYX1
Study NCT01625598 — intervention group
Intervention type: PROCEDURE
Intervention: Photography of the retina
Description: Every subject will undergo photography of the retina in both eyes
Study NCT02081703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection 6 mL
Description: 6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Study NCT02081703 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection 10 mL
Description: 10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Study NCT02878863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paeoniflorin + phosphatidylcholine or silymarin
Study NCT01625598 — intervention group
Intervention type: PROCEDURE
Intervention: Retinal photography
Description: Device~Subjects will have photography of both eyes
Study NCT01350349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Adaptation Therapy (PATH)
Description: Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
Study NCT02878863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phosphatidylcholine or silymarin
Study NCT00347269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
Study NCT00347269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychotropic medication optimization
Description: For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
Study NCT00347269 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants in the control group will receive standard treatment from their PCP.
Study NCT01013571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: pre-filled disposable pen, in package of 5.
Study NCT01013571 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apidra (insulin glulisine)
Description: pre-filled disposable pen, in package of 5
Study NCT00849992 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Imiquimod 5%
Description: Imiquimod 5% cream used three days a week for 4 weeks
Study NCT00849992 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Photodynamic therapy
Description: Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.
Study NCT03032484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
Study NCT03032484 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVB-2640
Description: TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.
Study NCT01350349 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive Therapy
Description: Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
Study NCT03549169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TOMAS
Description: Intervention focused on decision making for the management of symptoms aimed at adults with heart failure.
Study NCT03549169 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Regular attention
Description: Regular attention focused on education for therapeutic adherence
Study NCT01333969 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ischemic Preconditioning
Description: In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components). In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
Study NCT03880019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT00002663 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus-specific cytotoxic T lymphocytes (EBV-CTLs)
Description: EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
Study NCT03880019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core Biopsy
Description: Undergo tumor biopsy
Study NCT03880019 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT03880019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Given PO
Study NCT03880019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT02592863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
Study NCT02592863 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will take placebo 3 times per day for 12 weeks
Study NCT04962113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TUBE BATH
Description: Wrap Tube Baht (immersion)
Study NCT00899301 — intervention group
Intervention type: OTHER
Intervention: biologic sample preservation procedure
Description: Tissue, urine and blood collection.
Study NCT04632654 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A personalized Physical Activity intervention with fitness graded Motion Exergames (PAfitME)
Description: A total of 7 weekly intervention sessions will occur in a period of 6 weeks. Week 0 is a setup session conducted at the participant's home, including equipment set up, safety instruction, personalized exergame prescription development, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 1 and 2 are coaching sessions delivered by the interventionist using the FaceTime application in iPad, including exergame minutes and prescription review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Week 3 is a progress session conducted at the participant's home. The personalized exergame prescription will be adjusted. This session also will include exergame minutes review, exergame physical activity practice, discussion of barriers and strategies, and Q\&A session. Weeks 4 and 5 are the same as weeks 1 and 2. Week 6 is the final session. Exergame platform will be picked up at the participant's home.
Study NCT04726527 — intervention group
Intervention type: DRUG
Intervention: Florbetapir F 18
Description: A single injection of 10 mCi (370 MBq) florbetapir F 18 will be administered by intravenous bolus injection.
Study NCT04726527 — intervention group
Intervention type: DEVICE
Intervention: Positron Emission Tomography
Description: PET Scan for brain imaging
Study NCT02176343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL
Description: Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
Study NCT04003038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy
Description: Receive wound care with NPWT
Study NCT04003038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound Care Management
Description: Receive wound care with a standard dressing (bandage)
Study NCT06571890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Narcotrend bispectral index anaesthesia monitor
Description: A bispectral index anaesthesia monitor collects simplified EEG via forehead electrodes and displays an index of 0-100, where an index of 40-60 is considered optimal
Study NCT06571890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mdoloris Anaesthesia Nociception Monitor
Description: A heart rate variability-based nociception monitor collects ECG-signal from electrodes on the patient's chest and displays an index of 0-100 where an index below 50 is considered nociceptive.
Study NCT03093415 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: elbasvir-grazoprevir (50 mg/100 mg)
Description: 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
Study NCT03093415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: elbasvir-grazoprevir (50 mg/100 mg)
Description: 12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
Study NCT03421002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micafungin
Description: Participants will receive micafungin 8 mg/kg per day via intravenous infusion for approximately 1 hour.
Study NCT01810731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Inactivated Influenza Vaccine (QIV)
Study NCT01810731 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Polio Vaccine
Study NCT01810731 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Double Dose QIV
Study NCT01696071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 5 mcg qd
Description: 2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning
Study NCT01696071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium 2.5 mcg bid
Description: 2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
Study NCT03314194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plant Based Diet
Description: Plant Based Diet for 4 Days Compared to Habitual Diet
Study NCT00579137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Campath -1H
Description: Given intravenous on Days -8,-7, and -6~Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients >15 kg to 30 kg the dose 5 mg; for patients > 30 kg the dose is 10 mg
Study NCT00579137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given intravenous on Days -8,-7,-6,-5, and -4~Dose is 30 mg/m2
Study NCT00579137 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD45
Description: Given intravenous over 6 hours on Days -5,-4,-3, and -2~Dose is 400 microgram/kg
Study NCT00579137 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: stem cells are infused on day 0
Study NCT01980147 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maCBT
Description: Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
Study NCT03685149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide Pill
Description: Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
Study NCT03685149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Flecainide Pill
Description: Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
Study NCT03685149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
Study NCT03685149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Flecainide pill or placebo 100 mg administered twice a day for 4 weeks each
Study NCT01655277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Adductor Canal Block
Study NCT01655277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Guided Femoral Nerve Block
Study NCT04025320 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraneural Facilitation
Description: Intraneural Facilitation utilizes three manual holds. Firstly, the contralateral joint is placed in a maximal loose-pack position to pressurize the nervous system and bias circulation from the artery into the epineurium. Now that we have increased this pressure we begin the secondary hold to bias the increased epineurial blood into the transperineurial vessels that bridge the epiperineum and the endoneurial capillaries of the site being treated. Now that the pressure has increased into the open endoneurial capillaries, the goal is to open up ischemic endoneurial capillaries and this is hypothesized to open by providing the third hold. The third hold is known as the sub hold and encourages blood flow through ischemic endoneurial capillaries that have increased resistance/pressure through the application of bernoulli's principle. This treatment will take 50-60 minutes.
Study NCT04025320 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: A physical therapist will perform the SHAM light therapy at the same site as the INF therapy location, at the Neuropathic Treatment Center. The SHAM light therapy will last 50-60 minutes and consists of using an anodyne unit for application of near-infrared light therapy. The unit will not be switched on, but the pads will be placed on the subject and the subject will be blinded to the unit being on. The anodyne therapy pads will be placed in the following locations on the affected lower limb: two on the plantar aspect of the foot in a T formation and one pad on the medial and lateral side of the calf. A double folded towel will be wrapped around the subject's foot at the electrode sites to blind the subject's from the light not emitting from the electrodes, due to the anodyne unit being off.
Study NCT04289493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Language and functional communication therapy
Description: 17 therapy sessions in which the patients will be asked to dubb words or sentences from television series previously considered functionally meaningful for them.
Study NCT00997763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE V
Description: everolimus-eluting stent
Study NCT00997763 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CYPHER
Description: sirolimus-eluting stent
Study NCT00989495 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brace
Description: Wearing a Thoraco-Lumbo-Sacral-Orthosis (TLSO) for a minimum of 20 hours per day
Study NCT04400331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valbenazine
Description: vesicular monoamine transporter 2 (VMAT2) inhibitor